Compare · RMD vs TELA
RMD vs TELA
Side-by-side comparison of ResMed Inc. (RMD) and TELA Bio Inc. (TELA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and TELA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.13B, about 1086.0x TELA ($31.4M).
- TELA has been more active in the news (14 items in the past 4 weeks vs 9 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 2 for TELA).
- Company
- ResMed Inc.
- TELA Bio Inc.
- Price
- -
- -
- Market cap
- $34.13B
- $31.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 9
- 14
- Recent ratings
- 25
- 2
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
TELA Bio Inc.
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest RMD
- 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
Latest TELA
- Chief Executive Officer Getz Heather C bought $8,311 worth of shares (12,500 units at $0.66), increasing direct ownership by 2% to 532,500 units (SEC Form 4)
- Chief Executive Officer Getz Heather C bought $10,467 worth of shares (15,000 units at $0.70), increasing direct ownership by 3% to 520,000 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.
- Amendment: TELA Bio Inc. filed SEC Form 8-K: Leadership Update
- SEC Form S-8 filed by TELA Bio Inc.
- SEC Form 10-Q filed by TELA Bio Inc.
- TELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TELA Bio Reports Second Quarter 2026 Financial Results
- Chief Executive Officer Getz Heather C was granted 500,000 shares, increasing direct ownership by 10,000% to 505,000 units (SEC Form 4)
- New insider Getz Heather C claimed ownership of 5,000 shares (SEC Form 3)